Intercept’s (ICPT) OCA Gets Fast Track Designation From FDA

Shares of Intercept Pharmaceuticals Inc. (ICPT) were up +16.97 or +7.25 percent to $251 per share in pre-market trading on Thursday, after the company announced late yesterday that the FDA had granted Fast Track designation for the companyâ s obeticholic acid (OCA). Intercept stock closed at $234.03 per share, down -5.89 or -2.45 percent in Wednesdayâ s regular trading session.

New York City based Intercept Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing new treatments for chronic liver disease, such as primary biliary cirrhosis. The companyâ s main product is obeticholic acid or OCA, a substance structurally akin to naturally occurring human bile acid. The drug, which is a first in its class, selectively binds and activates â

Published on May 29, 2014

By Jay Hawk

Jay Hawk enjoyed a 12-year professional financial markets career incorporating extensive first hand futures and options experience obtained by trading in the stock, commodity and forex markets on U.S. exchanges. Since retiring as a full-time financial market professional, he has been actively trading stock, commodities, forex and options for his own account and managing funds for others, as well as writing financial market commentary and educational articles.